Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States
Authors' conclusion
Real-world evidence suggests multimorbidity among tirzepatide initiators, slower tirzepatide dose escalation than in clinical trials, and clinically meaningful weight reduction among people persisting on tirzepatide for ≥ 6 months.
Study context
- Population
- US adults without T2D initiating tirzepatide (May 13, 2022-May 24, 2023); mean age 46.0 years, 75.6 % female, mean BMI 37.1 kg/m²
- Exposure
- Overall vs obesity management medication (OMM)-eligible vs Persistent+GLP-1 naive
- Overalln = 4,177
- Persistent+GLP-1 naiven = 200
- Outcome
- Weight reduction (Persistent+GLP-1 naive cohort with pre/post weight)
- Follow-up
- 6-months post-index
Methodological detailsHealthcare Integrated Research Database, claims-based
- Healthcare Integrated Research Database
- Claims-based
Main finding
As reported in the abstract
| Group | Value | ≥ 5 % weight reduction | ≥ 10 % weight reduction |
|---|---|---|---|
| Persistent+GLP-1 naive | mean 12.9 % | 88.5 % | 69.0 % |
Persistent+GLP-1 naive
Valuemean 12.9 %
≥ 5 % weight reduction88.5 %
≥ 10 % weight reduction69.0 %
Observational data: associations, not effects.
Further findings
Obesity-related complications at baseline (Overall cohort)
%
- ≥1 ORC
- 73.8
- ≥2 ORCs
- 51.0
Tirzepatide persistence and dose (OMM-eligible cohort) · 6-months post-index
%
- Persistence
- 73.8
- Receiving <10 mg tirzepatide by sixth prescription fill
- 56.2
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States. Diabetes Metab. Published 7 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →